109351-34-0 Usage
Uses
Used in Pharmaceutical Industry:
(R)-Terazosin is used as a therapeutic agent for the treatment of various medical conditions, primarily related to the urinary and cardiovascular systems. Its application as an α-1-adrenergic blocker helps in managing symptoms such as high blood pressure, benign prostatic hyperplasia (BPH), and other conditions where the constriction or dilation of blood vessels is a concern.
Additionally, due to its selective blocking action, (R)-Terazosin may also be utilized in research and development for the discovery of new drugs targeting α-1 adrenergic receptors, potentially leading to novel treatments for a range of diseases and disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 109351-34-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,9,3,5 and 1 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 109351-34:
(8*1)+(7*0)+(6*9)+(5*3)+(4*5)+(3*1)+(2*3)+(1*4)=110
110 % 10 = 0
So 109351-34-0 is a valid CAS Registry Number.
109351-34-0Relevant academic research and scientific papers
R(+)-terazosin
-
, (2008/06/13)
R(+)-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-6,7-dimethoxy-4-quinazolinamine hydrochloride or a pharmaceutically acceptable salt or hydratet hereof (terazosin), substantially free of the S(-)-enantiomer.
Sustained-release drug dosage units
-
, (2008/06/13)
A sustained-release coating composition is described that contains an ethylcellulose and/or a methacrylic methylester together with a plasticizer and a detackifying agent. Sized drug granules are coated with this composition and then mixed with a polymeric composition containing at least one viscosity agent and formed into drug dosage units for the administration and sustained release of the drug in a patient. The sustained-release drug dosage units described produce a continuous, slow release of the drug at a therapeutically effective dosage level when administered to a patient.
